Cargando…
Prioritising systemic cancer therapies applying ESMO’s tools and other resources to assist in improving cancer care globally: the Kazakh experience
BACKGROUND: In Kazakhstan, cancer is the second leading cause of death with a major public health and economic burden. In the last decade, cancer care and cancer medicine costs have significantly increased. To improve the efficiency and efficacy of cancer care expenditure and planning, the Kazakhsta...
Autores principales: | Latino, N.J., Galotti, M., Cherny, N.I., de Vries, E.G.E., Douillard, J.-Y., Kaidarova, D., Ilbawi, A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8897160/ https://www.ncbi.nlm.nih.gov/pubmed/35246325 http://dx.doi.org/10.1016/j.esmoop.2021.100362 |
Ejemplares similares
-
ESMO Designated Centres of Integrated Oncology and Palliative Care (ESMO DCs): education, research and programme development survey
por: Kreye, G., et al.
Publicado: (2022) -
Detailed statistical assessment of the characteristics of the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) threshold rules
por: Dafni, Urania, et al.
Publicado: (2017) -
“The first ones now, will later be last”: understanding the importance of historical context when reading ESMO-MCBS scores
por: Cherny, N.I., et al.
Publicado: (2022) -
Lessons learnt from scoring adjuvant colon cancer trials and meta-analyses using the ESMO-Magnitude of Clinical Benefit Scale V.1.1
por: Knapen, Daan Geert, et al.
Publicado: (2020) -
PB2707: ESMO-MAGNITUDE OF CLINICAL BENEFIT SCALE FOR HAEMATOLOGICAL MALIGNANCIES (ESMO-MCBS:H) VERSION 1.0
por: Kiesewetter, Barbara, et al.
Publicado: (2023)